Assessing the impacts of several algae-based diets on cultured European abalone (Haliotis tuberculata)

The effects of different algal diets on the mortality, apparent ingestion, weight, length and conversion rates of the European abalone (Haliotis tuberculata) maintained in a semi-closed seawater system throughout the year were compared. Various combinations of red algae (Palmaria palmata, Ceramium rubrum and Chondrus crispus cultured or harvested from the natural environment, as well as Porphyra spp. collected), brown algae (Laminaria digitata) and green algae (fresh or frozen Ulva intestinalis) were tested. The results showed that P. palmata, C. rubrum and U. intestinalis administered alone were associated with significantly higher weight growth rates than the other species of algae tested. However, some combinations of algae (i.e. different proportions of L. digitata in association with P. palmata) were more favorable for weight increase when compared with the expected rates calculated for the diet based on L. digitata alone. Limiting the amount of any of these foods substantially reduced the conversion rate. Seasonal trends were apparent in both weight increase and food conversion rates, with the result that growth in weight on a diet of L. digitata was fastest in summer. Growth on P. palmata was faster in each season, and reached a maximum in early spring. The data collected allowed us to model weight increase and month-to-month food conversion rates for a diet based on P. palmata and L. digitata. The data obtained in this study were coupled with data regarding the availability of algae during the year, enabling us to suggest an optimal diet for each of the four seasons. Finally, the effects of different algae diets were investigated on hemocyte parameters, and the result suggested that P. palmata would reinforce the immune system of abalone

Deficits of psychomotor and mnesic functions across aging in mouse lemur primates.

Owing to a similar cerebral neuro-anatomy, non-human primates are viewed as the most valid models for understanding cognitive deficits. This study evaluated psychomotor and mnesic functions of 41 young to old mouse lemurs (Microcebus murinus). Psychomotor capacities and anxiety-related behaviors decreased abruptly from middle to late adulthood. However, mnesic functions were not affected in the same way with increasing age. While results of the spontaneous alternation task point to a progressive and widespread age-related decline of spatial working memory, both spatial reference and novel object recognition (NOR) memory tasks did not reveal any tendency due to large inter-individual variability in the middle-aged and old animals. Indeed, some of the aged animals performed as well as younger ones, whereas some others had bad performances in the Barnes maze and in the object recognition test. Hierarchical cluster analysis revealed that declarative-like memory was strongly impaired only in 7 out of 25 middle-aged/old animals. These results suggest that this analysis allows to distinguish elder populations of good and bad performers in this non-human primate model and to closely compare this to human aging.journal article20142015 01 09importe

The Athena X-ray Integral Field Unit: a consolidated design for the system requirement review of the preliminary definition phase

The Athena X-ray Integral Unit (X-IFU) is the high resolution X-ray spectrometer studied since 2015 for flying in the mid-30s on the Athena space X-ray Observatory. Athena is a versatile observatory designed to address the Hot and Energetic Universe science theme, as selected in November 2013 by the Survey Science Committee. Based on a large format array of Transition Edge Sensors (TES), X-IFU aims to provide spatially resolved X-ray spectroscopy, with a spectral resolution of 2.5 eV (up to 7 keV) over a hexagonal field of view of 5 arc minutes (equivalent diameter). The X-IFU entered its System Requirement Review (SRR) in June 2022, at about the same time when ESA called for an overall X-IFU redesign (including the X-IFU cryostat and the cooling chain), due to an unanticipated cost overrun of Athena. In this paper, after illustrating the breakthrough capabilities of the X-IFU, we describe the instrument as presented at its SRR (i.e. in the course of its preliminary definition phase, so-called B1), browsing through all the subsystems and associated requirements. We then show the instrument budgets, with a particular emphasis on the anticipated budgets of some of its key performance parameters, such as the instrument efficiency, spectral resolution, energy scale knowledge, count rate capability, non X-ray background and target of opportunity efficiency. Finally, we briefly discuss the ongoing key technology demonstration activities, the calibration and the activities foreseen in the X-IFU Instrument Science Center, touch on communication and outreach activities, the consortium organisation and the life cycle assessment of X-IFU aiming at minimising the environmental footprint, associated with the development of the instrument. Thanks to the studies conducted so far on X-IFU, it is expected that along the design-to-cost exercise requested by ESA, the X-IFU will maintain flagship capabilities in spatially resolved high resolution X-ray spectroscopy, enabling most of the original X-IFU related scientific objectives of the Athena mission to be retained. The X-IFU will be provided by an international consortium led by France, The Netherlands and Italy, with ESA member state contributions from Belgium, Czech Republic, Finland, Germany, Poland, Spain, Switzerland, with additional contributions from the United States and Japan.The French contribution to X-IFU is funded by CNES, CNRS and CEA. This work has been also supported by ASI (Italian Space Agency) through the Contract 2019-27-HH.0, and by the ESA (European Space Agency) Core Technology Program (CTP) Contract No. 4000114932/15/NL/BW and the AREMBES - ESA CTP No.4000116655/16/NL/BW. This publication is part of grant RTI2018-096686-B-C21 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. This publication is part of grant RTI2018-096686-B-C21 and PID2020-115325GB-C31 funded by MCIN/AEI/10.13039/501100011033

The Athena X-ray Integral Field Unit: a consolidated design for the system requirement review of the preliminary definition phase

The Athena X-ray Integral Unit (X-IFU) is the high resolution X-ray spectrometer, studied since 2015 for flying in the mid-30s on the Athena space X-ray Observatory, a versatile observatory designed to address the Hot and Energetic Universe science theme, selected in November 2013 by the Survey Science Committee. Based on a large format array of Transition Edge Sensors (TES), it aims to provide spatially resolved X-ray spectroscopy, with a spectral resolution of 2.5 eV (up to 7 keV) over an hexagonal field of view of 5 arc minutes (equivalent diameter). The X-IFU entered its System Requirement Review (SRR) in June 2022, at about the same time when ESA called for an overall X-IFU redesign (including the X-IFU cryostat and the cooling chain), due to an unanticipated cost overrun of Athena. In this paper, after illustrating the breakthrough capabilities of the X-IFU, we describe the instrument as presented at its SRR, browsing through all the subsystems and associated requirements. We then show the instrument budgets, with a particular emphasis on the anticipated budgets of some of its key performance parameters. Finally we briefly discuss on the ongoing key technology demonstration activities, the calibration and the activities foreseen in the X-IFU Instrument Science Center, and touch on communication and outreach activities, the consortium organisation, and finally on the life cycle assessment of X-IFU aiming at minimising the environmental footprint, associated with the development of the instrument. Thanks to the studies conducted so far on X-IFU, it is expected that along the design-to-cost exercise requested by ESA, the X-IFU will maintain flagship capabilities in spatially resolved high resolution X-ray spectroscopy, enabling most of the original X-IFU related scientific objectives of the Athena mission to be retained. (abridged).Comment: 48 pages, 29 figures, Accepted for publication in Experimental Astronomy with minor editin

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

Rearing practices identified as risk factors for ostreid herpesvirus 1 (OsHV-1) infection in Pacific oyster Crassostrea gigas spat

Early detection of Pacific oyster spat infected with ostreid herpesvirus 1 (OsHV-1) could prevent introduction of OsHV-1-infected individuals into farming areas or onshore rearing facilities, thus reducing the risk of infection of naïve oysters in such production systems. Experiments were conducted on several hundred oyster spat provided by producers in order to examine whether early rearing practices could be considered as potential risk factors for (1) OsHV-1 infection as detected by molecular methods and (2) spat mortality experimentally induced through thermal challenge. Spat groups collected on oyster beds and hatchery spat reared in growout areas during summer exhibited higher viral DNA contamination and mortalities during the trial than spat kept in onshore rearing facilities. Quantification of viral DNA before and during the trial showed that infection prevalence and intensity changed over time and revealed latent infection initially unsuspected in 3 of 10 groups. Thermal challenge induced a clear increase in the probability of detecting infected individuals, particularly for groups exhibiting significant prevalence of OsHV-1-contaminated spat prior to the challenge. The use of detection methods are discussed in relation to early rearing practices and disease control strategies.La détection précoce des lots de naissain d'huître creuse porteurs du virus OsHV-1 pourrait permettre d'éviter leur introduction dans des zones ou des installations d'élevage (en mer, ou à terre) jusque là épargnées par les mortalités de naissain. L'étude rapportée ici s'intéressait à l'effet des pratiques d'élevage "précoces" sur : 1) la probabilité de détection de l'OsHV-1 par les méthodes moléculaires de diagnostic et 2) la probabilité de mortalité révélée au moyen d'un protocole expérimental de conditionnement zootechnique du naissain. Les résultats montrent que les lots de naissain gardés isolés dans des structures d'élevage à terre présentent une probabilité de détection de l'OsHV-1 moindre que les lots issus de captage naturels, ou que les lots d'écloserie prégrossis en milieu naturel. L’utilisation conjointe du protocole expérimental de conditionnement, et des méthodes moléculaires destinées à quantifier l'ADN viral, a permis la révélation d'une infection latente, jusque-là insoupçonnée, chez 3 des 10 lots testés ici. Le conditionnement des naissains a ainsi induit une augmentation nette de la prévalence (ou de la fréquence de détection d'individus infectés) à l'échelle du groupe de naissain suivi, ainsi que du niveau moyen de contamination individuelle. La discussion de l'article portera sur ces aspects, et sur l'emploi des méthodes de détection précoce appliquée à l'amélioration des pratiques d'élevage et du contrôle des maladies infectieuses

Les syndromes parkinsoniens médicamenteux

Le syndrome parkinsonien (SP) est un syndrome moteur, défini par la présence d'une akinésie, associée à au moins un des symptômes suivants : rigidité extrapyramidale, tremblement de repos ou instabilité posturale. Son origine médicamenteuse doit toujours être évoquée devant l'apparition ou l'aggravation du SP chez un patient prenant un traitement. En effet, c'est la cause la plus fréquente des SP secondaires. De nombreux traitements peuvent induire ou aggraver un SP. Les principaux médicaments impliqués sont les antipsychotiques et autres neuroleptiques (jusqu'à deux tiers des étiologies médicamenteuses), et les inhibiteurs calciques. Le risque de syndrome parkinsonien iatrogène (SPI) est pour les antipsychotiques souvent dose-dépendant et proportionnel au niveau d'occupation des récepteurs dopaminergiques D2 au niveau striatal. Ce risque est moindre pour les antipsychotiques de seconde génération par rapport aux neuroleptiques classiques. Parmi les autres traitements, plus rarement mis en cause, on retrouve les antidépresseurs sérotoninergiques ou tricycliques, le lithium, l'acide valproïque, et d'autres traitements pour lesquels le mécanisme d'action reste incertain. S'il existe cliniquement des différences entre le SP médicamenteux et la maladie de Parkinson idiopathique (MPI), le principal critère d'imputabilité est chronologique : la régression des symptômes à l'arrêt du traitement, observée dans 40–74 % des cas, survient dans un délai très variable, en moyenne de 3 mois. Néanmoins, la persistance des troubles malgré l'arrêt du traitement doit faire évoquer une autre étiologie, notamment une MPI révélée par le traitement, ce qui est le cas pour 15 % des patients